Radioactive injection targets Hard-to-Treat cancers in early trial
NCT ID NCT07274852
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a radioactive drug called lutetium BL-ARC001 in 22 people with advanced lung, breast, head and neck, or other solid tumors that have stopped responding to standard therapies. The drug is given by IV infusion over a 6-week cycle. The main goals are to check safety, find the best dose, and get a first look at whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutetium [177Lu]-BL-ARC001 injection
What this could lead to
If successful, this could lead to a new targeted radiation therapy for several advanced solid tumors that have not responded to standard treatments.
What could go wrong
This is a very early Phase I trial with only 22 participants, so safety and dosing are still being determined. The treatment may not shrink tumors or could cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
Contact
Contact
Contact